Richard Stone, MD and Harry Erba MD, PhD
In this episode, “New AML Therapies: For Whom and When?”, Richard Stone, MD and Harry Erba MD, PhD discuss the status of recently-approved options for AML (acute myeloid leukemia) and their impact on algorithms and patient care.
After four decades with AML treatment remaining relatively unchanged, the long drought was broken in 2017 -2018 with approvals of several new agents,: midostaurin for addition to chemotherapy in patients with mutant FLT3, enasidenib and ivosidenib for relapsed/refractory AML with isocitrate dehydrogenase-2 (IDH2) mutation or IDH1 mutation, respectively, the re-introduction of gemtuzumab ozogamicin in conjunction with standard chemotherapy in CD33-positive cases, and the novel chemotherapy CPX-351 in secondary AML. All of the new therapies have shown improved response in their target populations, with some also demonstrating improved overall survival. These practice-changing advances have led to substantially revised treatment guidelines and, for the first time, the potential for individualized therapy in AML.